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ORIGINAL ARTICLEMolecular characterization of methicillin-resistant Staphylococcus aureus in
nosocomial infections in a tertiary-care facility: emergence of new clonal
complexes in Saudi ArabiaA. Senok1, R. Ehricht4,5, S. Monecke4,5,6, R. Al-Saedan2 and A. Somily3
1) Department of Microbiology and Immunology, College of Medicine, Alfaisal University, 2) Department of Clinical Laboratory Sciences, College of Applied Medical
Science, King Saud University, 3) Department of Pathology and Laboratory Medicine, College of Medicine, King Khalid University Hospital and King Saud University,
Riyadh, Saudi Arabia, 4) Alere Technologies GmbH, 5) InfectoGnostics Research Campus, Jena and 6) Institute for Medical Microbiology and Hygiene, Technische
Universität Dresden, Dresden, GermanyAbstractChanges in the molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) continue to be reported. This study was carried out
to characterize MRSA isolates in Saudi Arabia. MRSA isolates causing nosocomial infections (n = 117) obtained from 2009–2015 at a tertiary-care
facility in Riyadh, Saudi Arabia, were studied. Molecular characterization of isolates was carried out using the StaphyType DNA microarray (Alere
Technologies, Jena, Germany). Fourteen clonal complexes (CC) were identiﬁed, with the most common being CC80 (n = 35), CC6 (n = 15), CC5
(n = 13) and CC22 (n = 12). With the exception of nine ST239 MRSA-III isolates, all others were of community-associated MRSA lineages. The
following strains are identiﬁed for the ﬁrst time in Saudi Arabia: ST8-MRSA-IV [PVL+/ACME+], USA300 (n = 1); ST72-MRSA-IV USA700 (n = 1);
CC5-MRSA-IV, [PVL+/edinA+], WA MRSA-121 (n = 1); CC5-MRSA-V+SCCfus, WA MRSA-14/109 (n = 2), CC97-MRSA-IV, WA MRSA-54/63;
CC2250/2277-MRSA-IV andWA MRSA-114. CC15-MRSA (n = 3) was identiﬁed for the ﬁrst time in clinical infection in Saudi Arabia. None of the
isolates harboured vancomycin resistance genes, while genes for resistance to mupirocin and quaternary ammonium compounds were found in
one and nine isolates respectively. Fifty-seven isolates (48.7%) were positive for Panton-Valentine leukocidin genes. While the staphylokinase (sak)
and staphylococcal complement inhibitor (scn) genes were present in over 95% of the isolates, only 37.6% had the chemotaxis-inhibiting protein
(chp) gene. Increasing occurrence of community-acquired MRSA lineages plus emergence of pandemic and rare MRSA strains is occurring in our
setting. Strict infection control practices are important to limit the dissemination of these MRSA strains.
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
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Disease Congress, 4–7 May 2016, Dubai, United Arab Emirates.IntroductionA shift in the epidemiology of methicillin-resistant Staphylococcus
aureus (MRSA) has been demonstrated, with reports of
community-acquired (CA) MRSA strains causing nosocomial© 2016 The Authors. Published by El
This is an open access artiinfections [1]. Published literature from the Arabian Gulf region
has shown the spread of CA-MRSA into the healthcare setting,
with differences in the predominant strains reported from
countries in the region [2–5].However, there are fewdata on the
molecular characterization of MRSA isolates in Saudi Arabia,
where a different population structure of MRSA might be ex-
pected as a result of the large number of pilgrims who visit the
country annually; the large immigrant workforces from the Indian
subcontinent, Maghreb countries, Egypt and Yemen; and a rela-
tive absence ofNorthern American and European tourists [6–8].
We carried out molecular characterization of MRSA isolates
causing nosocomial infections in a hospital in Saudi Arabia. The
ﬁndings indicate emergence of new MRSA clonal complexes.New Microbe and New Infect 2016; 14: 13–18
sevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
http://dx.doi.org/10.1016/j.nmni.2016.07.009
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Clonal
complex Strain afﬁliation Total
CC1 CC1-MRSA-IV, WA MRSA-1/57 1
CC5 CC5-MRSA-IV+SCCfus, Maltese clone (n = 7) 13
CC5-MRSA-V+SCCfus, WA MRSA-14/109 (n = 3)
CC5-MRSA-IV, [PVL+] (n = 2)
CC5-MRSA-IV, [PVL+/edinA+], WA MRSA-121 (n = 1)
CC6 CC6-MRSA-IV, WA MRSA-51 15
CC8 ST239-MRSA-III+ccrC, Vienna/Hungarian/Brazilian
clone (n = 9)
11
ST8-MRSA-IV [PVL+/ACME+], USA300 (n = 1)Specimen collection and bacterial strains
The study was carried out at the King Khalid University Hos-
pital in Riyadh, Saudi Arabia. Ethical approval was obtained from
the hospital ethics committee. Archived MRSA isolates associ-
ated with clinical infection identiﬁed from 2009 to 2015 were
studied. Bacterial identiﬁcation and antibiotic susceptibility
testing were performed using standard laboratory techniques
and the automated MicroScan Walkaway 96 plus System
(Siemens Healthcare Diagnostic) in accordance with Clinical
and Laboratory Standards Institute guidelines [9]. Methicillin
resistance was conﬁrmed on Mueller-Hinton agar using the disk
diffusion method to demonstrate resistance to oxacillin and
30 mg cefoxitin disks [9].
Array procedures
Molecular characterization was carried out using the StaphyType
DNA microarray (Alere Technologies, Jena, Germany). The
included target genes, primer and probe sequences and proced-
ures have been published previously [10]. Brieﬂy, MRSA isolates
were collected from Columbia blood agar, and DNA extraction
was carried out by enzymatic lysis [10] followed by puriﬁcation
using a commercially available kit utilizing spin columns (Qiagen,
Hilden, Germany). The puriﬁed DNA was used as template in a
linear primer elongation reaction, during which biotin-16-dUTP
was incorporated into the resulting amplicons and the single-
stranded DNA products were hybridized stringently to the
microarray. Incubation with horseradish peroxidase–
streptavidin conjugate, which binds to biotin labels, was carried
out, and a dye was added which precipitated in the presence of
the peroxidase, resulting in the formation of visible spots where
hybridization had occurred. Microarray images were taken and
analysed with a dedicated reader and software (Alere Technol-
ogies). Assignment to clonal complexes and sequence types, as
well as identiﬁcation of epidemic strains was carried out fully
automatically with the same software module [8,10].ST72-MRSA-IV, USA700 (n = 1)
CC15 CC15-MRSA (n = 1) 3
CC15-MRSA-V+SCCfus (n = 2)
CC22 CC22-MRSA-IV [fnbB+], UK-EMRSA-15/Barnim
EMRSA variant (n = 1)
12
+
ResultsCC22-MRSA-IV [PVL ] (n = 4)
CC22-MRSA-IV [tst1+],/Middle Eastern variant (n = 7)
CC30 CC30-MRSA-IV [PVL+], Southwest Paciﬁc clone (n = 6) 8
CC30-MRSA-? [VI+fus composite ] (n = 2)
CC80 CC80-MRSA-IV [PVL+], European CA-MRSA clone 35
CC88 CC88-MRSA-IV [PVL+] 6
CC97 CC97-MRSA-V [fusC+] (n = 7) 8
CC97-MRSA-IV, WA MRSA-54/63 (n = 1)
CC2250 CC2250/2277-MRSA-IV, WA MRSA-114 2
CC96 CC96-MRSA-IV 1
CC45 CC45/agrIV-MRSA-IV, WA MRSA-23 1
CC913 ST913-MRSA-IV 1
Total 117
MRSA, methicillin-resistant Staphylococcus aureus; UK-EMRSA, United Kingdom
epidemic MRSA; WA MRSA, Western Australia MRSA.A total of 117 isolates obtained from wound swabs (n = 83),
blood cultures (n = 26), endotracheal aspirates (n = 4), sputum
(n = 2) and urine (n = 2) were studied. A majority of the pa-
tients were male (n = 62), and their mean ± standard deviation
age was 34.9 ± 26.1 years. Most of the patients (83%) were
Saudi nationals. There was 100% concordance in the pheno-
typic and genotypic MRSA identiﬁcation. All isolates were
susceptible to vancomycin.© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceThere was a wide clonal diversity, with 14 clonal complexes
(CC) being identiﬁed. The most common CCs were CC80,
CC6, CC5 and CC22 (Table 1). The most prevalent strain
(n = 35; 29.9%) was CC80-MRSA-IV [PVL+] (European CA-
MRSA clone). Although one isolate with a truncated/atypical
SCCmec element was identiﬁed, we did not ﬁnd Panton-
Valentine leukocidin (PVL)-negative variants of CC80. All the
15 CC6 strains carried SCCmec IV and were identical to
Western Australia (WA) MRSA-51. The 13 CC5 strains
belonged, based on hybridization patterns, to four distinct
strains, with the predominant one being CC5-MRSA-IV+SCC-
fus (“Maltese clone”) (Table 1). Twelve isolates were identiﬁed
as CC22, with the Middle Eastern variant CC22-MRSA-IV
[tst1+] being the most prevalent (n = 7). The only classical
hospital-acquired (HA)-MRSA isolates identiﬁed were nine
CC8 isolates, which were ST239-MRSA-III+SCCmer (Vienna/
Hungarian/Brazilian Clone).
Our data and actual literature indicate the ﬁrst report of the
following strains in Saudi Arabia: ST8-MRSA-IV [PVL+/ACME+],
USA300 (n = 1); ST72-MRSA-IV USA700 (n = 1); CC5-MRSA-
IV, [PVL+/edinA+], WA MRSA-121 (n = 1); CC5-MRSA-
V+SCCfus, WA MRSA-14/109 (n = 2); CC97-MRSA-IV, WA
MRSA-54/63 (n = 1); and CC2250/2277-MRSA-IV, WA MRSA-
114. The CC15-MRSA strain (n = 3) was identiﬁed for the ﬁrst
time in clinical infection in Saudi Arabia. Additionally, a strain
was observed that was either a CC22-MRSA-IV [fnbB-,sec/l−],
United Kingdom epidemic MRSA-15 (UK-EMRSA-15)/Barnim
EMRSA or a tst1-negative deletion variant of a strain commonlyiology and Infectious Diseases, NMNI, 14, 13–18
nses/by-nc-nd/4.0/).
TABLE 2. Distribution of virulence and resistance gene
markers in 117 isolates
Virulence and resistance genes
Isolates
positive
for gene
n %
Accessory gene regulator allele I agrI 46 39.3
Accessory gene regulator allele II agrII 17 14.5
Accessory gene regulator allele III agrIII 51 43.6
Accessory gene regulator allele IV agrIV 6 5.1
Alternate penicillin-binding protein 2, deﬁning MRSA mecA 117 100.0
Mercury resistance operon merA 7 6.0
merB 7 6.0
SCCmec XI mecC 0 0.0
blaZ-SCCmec XI 0 0.0
β-Lactamase blaZ 105 89.7
β-Lactamase repressor (inhibitor) blaI 105 89.7
β-Lactamase regulatory protein blaR 105 89.7
Rrna adenine N-6-methyl-transferase, erythromycin/
clindamycin resistance
ermA 10 8.5
Erythromycin/clindamycin resistance ermB 0 0.0
Erythromycin/clindamycin resistance ermC 21 17.9
Linco-samid-nucleo-tidyltrans-ferase linA 6 5.1
Energy-dependent efﬂux of erythromycin msrA 5 4.3
Bifunctional enzyme Aac/Aph, gentamicin resistance aacA-aphD 14 12.0
Amino-glycoside adenyl-transferase, tobramycin
resistance
aadD 10 8.5
3050-Aminog-lycoside phospho-transferase, neo-/
kanamycin resistance
aphA3 42 35.9
Strepto-thricine-acetyl-transferase sat 42 35.9
Dihydro-folate reductase type 1 dfrA 9 7.7
Fusidic acid resistance far1 34 29.1
Hypothetical protein associated with fusidic acid
resistance
Q6GD50 (fusC) 23 19.7
Mupirocin resistence protein mupR 1 0.9
Tetracycline-resistance tetK 31 26.5
Tetracycline-resistance tetM 10 8.5
Chloramphenicol acetyltransferase cat 2 1.7
23S rRNA methyltransferase cfr 0 0.0
Chloramphenicol/ﬂorfenicol exporter fexA 1 0.9
Metallothiol transferase fosB 52 44.4
fosB-plasmid 7 6.0
Quaternary ammonium compound resistance
protein A
qacA 9 7.7
Quaternary ammonium compound resistance
protein C
qacC 0 0.0
Transport/efﬂux protein tetEfﬂux 103 88.0
Vancomycin resistance gene vanA 0 0.0
Vancomycin resistance gene from enterococci and
Clostridium
vanB 0 0.0
Teicoplanin resistance gene from enterococci vanZ 0 0.0
Toxic shock syndrome toxin 1 tst1 (consensus) 10 8.5
Panton-Valentine leukocidin F component lukF-PV 57 48.7
Panton-Valentine leukocidin S component lukS-PV 57 48.7
Staphylokinase sak 113 96.6
Chemotaxis-inhibiting protein chp 44 37.6
Staphylocccal complement inhibitor scn 116 99.1
Exfoliative toxin serotype A etA 1 0.9
Exfoliative toxin serotype B etB 0 0.0
Exfoliative toxin D etD 36 30.8
Epidermal cell differen-tiation inhibitor edinA 2 1.7
Epidermal cell differentiation inhibitor B edinB 36 30.8
Epidermal cell differentiation inhibitor C edinC 0 0.0
Arginine catabolic mobile element locus ACME 1 0.9
MRSA, methicillin-resistant Staphylococcus aureus.
NMNI Senok et al. New MRSA clones in Saudi Arabia 15observed in the Middle East (“Gaza epidemic strain”) (n = 1)
(Table 1), thus warranting further investigations on differenti-
ation and molecular epidemiology of CC22 MRSA.
Table 2 shows the distribution of resistance and virulence
genes. The most predominant accessory gene regulator alleles
were agrI and agrIII. None of the isolates harboured the
SCCmec XI and/or the mecC gene. A majority of isolates
(n = 105; 89.7%) carried the β-lactamase operon. Twenty-three
isolates (19.7%) carried the fusidic acid resistance gene fusC© 2016 The Authors. Published by Elsevier Ltd on behal
This is an open access artic(Q6GD50). Only one isolate had the mupirocin resistance gene
(mupR), and the gene encoding the quaternary ammonium
compound resistance protein A (qacA) was found in nine iso-
lates (7.7%). Almost half of the isolates were PVL positive
(n = 57; 48.7%). While the staphylokinase (sak) and staphylo-
coccal complement inhibitor (scn) genes were present in over
95% of the isolates, only 37.6% had the chemotaxis-inhibiting
protein (chp) gene (Table 2). The arginine catabolic mobile
element (ACME) locus was present in only one isolate (CC8-
MRSA-IV, “USA300”).DiscussionAn increasing trend of MRSA endemicity has been reported in
healthcare facilities in Saudi Arabia, with CA-MRSA contrib-
uting to the burden of infections [8]. However, there are few
data describing the MRSA clonal complexes in Saudi Arabia
[6–8]. A 2005 report showed the predominance of the
hospital-acquired lineage ST239 MRSA-III [7]. Using DNA
microarray-based typing, a high diversity of clonal complexes
with predominance of CC8/ST239-III, CC22-IV, CC30-IV and
CC80-IV was demonstrated in 2011–2012 in a tertiary-care
hospital in Riyadh [8]. The ﬁndings from our study also show
a high diversity in MRSA and suggest a potential for rapid
changes. This is rather different than the situation in the United
States, where “USA300” dominates, or the Western Europe,
where PVL-negative CC22-MRSA-IV (UK-EMRSA-15/Barnim
EMRSA) are most abundant [1]. In addition, our ﬁndings
conﬁrm that a shift has occurred, with what are presumably
CA-MRSA clonal lineages now predominating within the
healthcare, setting as majority of the isolates harboured
SCCmec IV and V [6,8]. Of signiﬁcance, however, is that we
now report the ﬁrst identiﬁcation of new MRSA strains,
including rare and pandemic ones, in Saudi Arabia.
CC5
In this study, CC5-MRSA-IV+SCCfus, Maltese clone strain, was
the predominant CC5. This strain, which was originally identi-
ﬁed in Malta, harbours the fusidic acid resistance marker
Q6GD50 (fusC), SCCmec IV and additional recombinase genes
[11]. As it has only been reported in one study in Saudi Arabia,
our ﬁnding represents the second reported identiﬁcation in the
country and the region [8]. Similar to previous report from
Saudi Arabia, we also identiﬁed CC5-MRSA-IV, [PVL+] (paedi-
atric clone, or USA800) [8]. This has been identiﬁed as the
second most predominant MRSA strain in Qatar [5]. Three
variants of PVL-positive CC5-MRSA-IV based on combination
of virulence genes have been described [10]. The WA MRSA-
121 is one of these variants, as it is a PVL-positive CC5-f of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 14, 13–18
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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previously identiﬁed in our region. CC5-MRSA-V has been
described in Australia, Ireland and the United Arab Emirates
[10]. Our identiﬁcation of two isolates designated as CC5-
MRSA-V [fusC+] represents the ﬁrst description of an isolate
very similar to WA MRSA-14 in Saudi Arabia.
CC6
All 15 CC6 strains were identical to WA MRSA-51 [12]. This is
similar to previous work in Riyadh in which all the CC6 strains
were WA MRSA-51 strains and represents its second
description in Saudi Arabia [8]. This strain has been described in
Australia and United Arab Emirates [10,12]. CC6 methicillin-
susceptible S. aureus (MSSA) has been reported as a common
clone in Middle Eastern camels; however, only one isolate was
identiﬁed in nasal colonization isolates in Riyadh [10,13].
CC8
A majority of the CC8 isolates belonged to the ST239-MRSA-
III+SCCmer (Vienna/Hungarian/Brazilian clone). Our ﬁndings
support recent data which indicates that this HA-MRSA strain,
which has been described as the oldest pandemic MRSA strain,
has been displaced by CA-MRSA strains in the hospital envi-
ronment in Saudi Arabia [8]. However, in a departure from the
2012 report by Monecke et al. [8] in which all CC8 isolates
were ST239, our ﬁndings indicate the appearance of two other
CC8 strains. We present the ﬁrst report of the pandemic
USA300 (ST8-MRSA-IV [PVL+/ACME+]) and USA700 (ST72-
MRSA-IV) in Saudi Arabia. USA300 is the dominant MRSA
strain in the United States, and although it has been identiﬁed in
Europe, the occurrence is much less frequent there [14,15]. In
our region, this strain has been described in the United Arab
Emirates and Qatar [5,10]. The ST72 strain belongs to CC8
according to the MLST (multilocus sequence typing) database,
but it typically yields a different hybridization proﬁle compared
to other CC8 strains. It has been suggested that this strain
probably arose as consequence of multiple recombination
events of the CC5 and CC8 genomes [10]. Our isolate was
USA700, which is a PVL-positive ST72-MRSA-IV strain. In our
region, it had been identiﬁed in the United Arab Emirates, and
our ﬁnding represents its ﬁrst identiﬁcation in Saudi Arabia
[10].
CC15
Although CC-15-MSSA is ubiquitous among healthy carriers,
CC15 MRSA remains rare [10]. Recent work from Riyadh,
Saudi Arabia, found CC15-MSSA as the predominant nasal
colonization MSSA isolate [13]. CC-15 MRSA isolates have
been identiﬁed in few reports [6,16,17]. Two CC-15 MRSA
isolates which were nasal colonizers were reported from Iran© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceand Saudi Arabia [6,17]. Our ﬁndings therefore indicate the ﬁrst
report of CC-15 MRSA isolate causing nosocomial infection in
the region.
CC22
Similar to a previous report from Saudi Arabia, both PVL-
positive and PVL-negative CC22 strains were identiﬁed [8].
The CC22-MRSA-IV UK-EMRSA 15 is a pandemic PVL-negative
strain which has very high incidence of 50–95% in Western
Europe and has also been described in Malta, Kuwait, the
United Arab Emirates and Qatar [5,10,18]. There is also a
Middle Eastern variant that differs from the true UK-EMRSA-15
in its SCCmec subtype (SCCmec IVa rather than IVh/j) and in
the presence of the tst1 gene. Our ﬁnding echoes previous
reports of the identiﬁcation of this strain in other reports from
the region [10]. PVL-positive CC22 MRSA-IV has been
described in Germany, Australia, England, Ireland, Hong Kong
and the United Arab Emirates [10]. This strain might be
widespread in the region, as they were also described in a
previous study from Saudi Arabia and in German patients with
ties to Turkey [8,10].
CC30
Six isolates belonged to the CC30-MRSA-IV [PVL+], Southwest
Paciﬁc clone (USA1100). This strain is widely distributed in the
Paciﬁc islands and was ﬁrst identiﬁed in New Zealand among
the Samoan immigrant population [10]. It is a widespread MRSA
clone and has been found in several European countries as well
as in Hong Kong, Taiwan and the United States [10]. In our
region, it has been described in Saudi Arabia, Kuwait, the
United Arab Emirates, Oman and Qatar [3,5,8]. The occur-
rence of this strain in our region could possibly be linked to the
large population of expatriates from the Paciﬁc region, in
particular the Philippines. In this study we identiﬁed a previously
undescribed CC30-MRSA-VI/SCCfus strain which was PVL-
positive. This strain differs from other known CC30 strains in
its carriage of SCCmec type VI with the fusidic acid resistance
gene marker.
CC80
The majority of our isolates were PVL-positive CC80-MRSA IV
(European CA-MRSA clone), which is in accordance with
previous reports from Saudi Arabia and from other countries in
the region [5,10,19,20]. This strain has also been shown to be
predominant in North Africa, which suggests a spread from
Europe into North Africa and the Middle East [21–23].
Conversely, this strain could have spread from these regions
into Europe as a consequence of travel to Turkey and the
Maghreb countries (which are both popular holiday destina-
tions and the homelands of large immigrant communities iniology and Infectious Diseases, NMNI, 14, 13–18
nses/by-nc-nd/4.0/).
NMNI Senok et al. New MRSA clones in Saudi Arabia 17Europe) [10]. In contrast to reports from France and Croatia as
well as a previous report from Saudi Arabia, no PVL-negative
variant of CC80 was identiﬁed in our study [8,24]. However,
we identiﬁed one variant, CC80-MRSA, which was PVL posi-
tive, which had a truncated/atypical SCCmec element lacking ccr
genes.
CC88
CC88-MRSA-IV strains carrying the exfoliative toxin gene etA
have been described in the Netherlands, Portugal, Angola,
Senegal and Japan [10]. The CC88-MRSA-IV strains we identi-
ﬁed in this study were PVL positive but lacked the etA gene. This
is in contrast to a previous report from Saudi Arabia in which
the CC88-MRSA-IV [PVL+] identiﬁed harboured the etA gene
[8].
CC97
This MRSA clonal complex has only been sporadically identiﬁed
in reports from Australia, France, the United Arab Emirates,
Kuwait and Egypt [10,25]. Seven of the eight CC97 strains in
this study were CC97-MRSA-V [fusC+] and were similar to
those previously identiﬁed in Saudi Arabia [8]. One CC97-
MRSA belonged to CC97-MRSA-IV (corresponding to WA
MRSA-54/63), which had not previously been described in Saudi
Arabia.
Two isolates of CC2250/2277-MRSA-IV, WA MRSA-114,
and one each of CC1-MRSA-IV, WA MRSA-1/57, CC45/
agrIV-MRSA-IV, WA MRSA-23 and CC913 were identiﬁed. The
CC1 isolate had SCCmec IV, lacked the SCCfus and was PVL
negative. CC1-MRSA isolates with these characteristics
included WA MRSA-57 and WA MRSA-1 [10]. The strain
afﬁliation for our isolate is therefore regarded as CC1-MRSA-
IV, WA MRSA-1/57, which has been described in Germany,
Ireland and Egypt [10]. This strain appears infrequent in our
setting; only one was identiﬁed in previous work in Saudi Arabia
[8]. The CC45/agrIV-MRSA-IV, WA MRSA-23 strain, which has
been linked to Hong Kong, South China and Australia, has
previously been reported in Saudi Arabia [8,10]. Our report of
CC2250/2277-MRSA-IV, WA MRSA-114 marks the ﬁrst
description of the Staphylococcus argenteus lineage MRSA in
Saudi Arabia. CC913 represents a rare group which had pre-
viously been identiﬁed in a Lebanese immigrant in Germany and
in subjects from the Negev region [10]. This ﬁrst identiﬁcation
in our setting supports the notion of a wider distribution of this
lineage in the Middle East.
The PVL genes (lukF-PV+lukS-PV) have been implicated as
playing a role in the development of skin and soft tissue in-
fections. Similar to our ﬁndings, high numbers of PVL-positive
strains have been reported from Algeria and the United Arab
Emirates [10,26]. However, our ﬁndings are higher compared© 2016 The Authors. Published by Elsevier Ltd on behal
This is an open access articto reports from some European countries [10,15,27,28]. Pre-
viously published data from Saudi Arabia showed a lower PVL
prevalence, ranging from 8% to 19% [29]. Reasons for this
difference are largely unknown; it could be speculated that
these PVL-positive MRSA have emerged from PVL-positive
MSSA. However, if this were the case, then frequency of
PVL-positive MSSA should also be high in our population.
Recent data on MSSA isolates from nasal colonization in Riyadh
showed very low prevalence of PVL genes [13]. A number of
other virulence genes were detected in different proportions. A
high prevalence of the staphylococcal complement inhibitor
(scn) and staphylokinase (sak) were observed. However,
chemotaxis-inhibiting protein (chp) was identiﬁed in fewer
isolates. These virulence genes have also been identiﬁed as
being widely distributed in MSSA associated with nasal coloni-
zation in Saudi Arabia [13].
Although studies have shown an increasing trend of pheno-
typic resistance to various antibiotics in CA-MRSA isolates
from Saudi Arabia, no vancomycin resistance has yet been re-
ported [30]. However, there are few data on the distribution of
resistance genes [8]. The DNA microarray used in this study
enabled us to describe a wide spectrum of resistance and
virulence genes. Our ﬁndings are in accordance to previously
reported work using this methodology to characterize MRSA
isolates from Saudi Arabia [8]. To better map the evolution of
resistance genes in MRSA isolates in our setting, further work
using robust methodologies such as the DNA microarray
approach are needed.
A limitation of this work is that it was carried out in a single
healthcare facility. However, the ﬁndings highlight the urgent
need for multicentre studies to elucidate the population
structure of MRSA in Saudi Arabia. Strict adherence to infection
control practices and continued surveillance using improved
technology are advocated.AcknowledgementRAS is supported by King Abdulaziz City for Science and
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